(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lopez P et al. | Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. | 2011 | J. Infect. Dis. | pmid:21606530 |
| Cen-Pacheco F et al. | Cytotoxic oxasqualenoids from the red alga Laurencia viridis. | 2011 | Eur J Med Chem | pmid:21616566 |
| Raouane M et al. | Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. | 2011 | J. Med. Chem. | pmid:21561161 |
| Nowosielski M and Hoffmann M | Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? | 2011 | J Mol Model | pmid:21562825 |
| Hernández-GarcÃa I et al. | [Adverse events after administration of A/H1N1 vaccine to patients]. | 2011 | Med Clin (Barc) | pmid:20199781 |
| Kaya K et al. | Thraustochytrid Aurantiochytrium sp. 18W-13a accummulates high amounts of squalene. | 2011 | Biosci. Biotechnol. Biochem. | pmid:22056449 |
| Celia C et al. | Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. | 2011 | Expert Opin Drug Deliv | pmid:22077480 |
| Tsai TF | MF59 adjuvanted seasonal and pandemic influenza vaccines. | 2011 | Yakugaku Zasshi | pmid:22129867 |
| Puig-Barberà J et al. | MF59™-adjuvanted seasonal influenza vaccine in young children. | 2011 | Expert Rev Vaccines | pmid:22043952 |
| Viganò A et al. | Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. | 2011 | Clin. Vaccine Immunol. | pmid:21795458 |
| Huijskens E et al. | Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. | 2011 | Clin. Vaccine Immunol. | pmid:21795459 |
| Wu J et al. | Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. | 2011 | Arch. Virol. | pmid:21110049 |
| Packwood DM and Phillips LF | A stochastic, local mode study of neon-liquid surface collision dynamics. | 2011 | Phys Chem Chem Phys | pmid:21042647 |
| Andrews N et al. | Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. | 2011 | J. Infect. Dis. | pmid:21148494 |
| Kajaste-Rudnitski A et al. | Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. | 2011 | AIDS | pmid:21150561 |
| Launay O et al. | Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. | 2011 | J. Infect. Dis. | pmid:21628666 |
| Piccialli V et al. | Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. | 2011 | Molecules | pmid:21709619 |
| O'Hagan DT et al. | MF59 adjuvant: the best insurance against influenza strain diversity. | 2011 | Expert Rev Vaccines | pmid:21506643 |
| Esposito S et al. | Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. | 2011 | Hum Vaccin | pmid:21508673 |
| AÄimoviÄ J et al. | Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. | 2011 | Biochem. Biophys. Res. Commun. | pmid:21531203 |
| Siedenburg G and Jendrossek D | Squalene-hopene cyclases. | 2011 | Appl. Environ. Microbiol. | pmid:21531832 |
| Tsai TF et al. | Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. | 2011 | Scand. J. Infect. Dis. | pmid:21534891 |
| Esposito S et al. | Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. | 2011 | Pediatrics | pmid:21464195 |
| Esposito S et al. | An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. | 2011 | Nephrol. Dial. Transplant. | pmid:20974645 |
| Montana M et al. | Safety review: squalene and thimerosal in vaccines. | 2010 Nov-Dec | Therapie | pmid:21176760 |
| Bhilwade HN et al. | Squalene as novel food factor. | 2010 | Curr Pharm Biotechnol | pmid:20874681 |
| Iannitti T and Palmieri B | An update on the therapeutic role of alkylglycerols. | 2010 | Mar Drugs | pmid:20948908 |
| Voyron S et al. | Antifungal activity of bis-azasqualenes, inhibitors of oxidosqualene cyclase. | 2010 | Mycoses | pmid:19549106 |
| Durando P et al. | MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. | 2010 | Expert Opin Biol Ther | pmid:20218923 |
| Taramino S et al. | Interactions of oxidosqualene cyclase (Erg7p) with 3-keto reductase (Erg27p) and other enzymes of sterol biosynthesis in yeast. | 2010 | Biochim. Biophys. Acta | pmid:19879375 |
| van Himbergen TM et al. | Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:19834104 |
| Keitel W et al. | Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. | 2010 | Vaccine | pmid:19835829 |
| Brunner R et al. | The ABC of clinical and experimental adjuvants--a brief overview. | 2010 | Immunol. Lett. | pmid:19895847 |
| Eroglu E and Melis A | Extracellular terpenoid hydrocarbon extraction and quantitation from the green microalgae Botryococcus braunii var. Showa. | 2010 | Bioresour. Technol. | pmid:20005092 |
| Kalvodova L | Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. | 2010 | Biochem. Biophys. Res. Commun. | pmid:20018176 |
| Camin F et al. | Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane. | 2010 | Rapid Commun. Mass Spectrom. | pmid:20499327 |
| Mantzouridou F and Tsimidou MZ | Observations on squalene accumulation in Saccharomyces cerevisiae due to the manipulation of HMG2 and ERG6. | 2010 | FEMS Yeast Res. | pmid:20550581 |
| Van Damme P et al. | Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. | 2010 | BMC Infect. Dis. | pmid:20504306 |
| Waddington CS et al. | Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. | 2010 | BMJ | pmid:20508026 |
| Beck F et al. | Queries about vaccines containing squalene. | 2010 | Immunol. Cell Biol. | pmid:20157330 |
| Gerpe A et al. | Naftifine-analogues as anti-Trypanosoma cruzi agents. | 2010 | Eur J Med Chem | pmid:20163894 |
| Warleta F et al. | Squalene protects against oxidative DNA damage in MCF10A human mammary epithelial cells but not in MCF7 and MDA-MB-231 human breast cancer cells. | 2010 | Food Chem. Toxicol. | pmid:20138105 |
| Sugihara N et al. | Novel fractionation method for squalene and phytosterols contained in the deodorization distillate of rice bran oil. | 2010 | J Oleo Sci | pmid:20103978 |
| Chen CC et al. | Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. | 2010 | Eur J Pharm Biopharm | pmid:20060469 |
| Spanova M et al. | Effect of lipid particle biogenesis on the subcellular distribution of squalene in the yeast Saccharomyces cerevisiae. | 2010 | J. Biol. Chem. | pmid:20032462 |
| Tsai T et al. | Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. | 2010 | Vaccine | pmid:19969117 |
| Narayan BH et al. | Modulation of doxorubicin-induced genotoxicity by squalene in Balb/c mice. | 2010 | Food Funct | pmid:21776469 |
| Bildstein L et al. | Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. | 2010 | J Control Release | pmid:20691740 |
| Weiss TL et al. | Raman spectroscopy analysis of botryococcene hydrocarbons from the green microalga Botryococcus braunii. | 2010 | J. Biol. Chem. | pmid:20705610 |
| Beran J et al. | A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. | 2010 | Clin Ther | pmid:21316535 |